•      Thu Nov 14 2024
Logo

COVISHIELD vaccine approved in Nepal



vaccine
FILE – This September 2020 photo provided by Johnson & Johnson shows a single-dose COVID-19 vaccine being developed by the company. A late-stage study of Johnson & Johnson’s COVID-19 vaccine candidate has been paused while the company investigates whether a study participant’s “unexplained illness” is related to the shot, the company announced Monday, Oct. 12, 2020. (Cheryl Gerber/Courtesy of Johnson & Johnson via AP, File)

KATHMANDU: The Department of Drug Administration has given permission for emergency use of the vaccine COVISHIELD against Covid-19 in Nepal.

The department has given conditional permission for the emergency use of the vaccine produced by the Serum Institute of India.

Covishield is an Indian version of the vaccine jointly developed by Oxford University and AstraZeneca. Two days before, the Department had published a notice for the registration of vaccines to be used for emergency use in Nepal.

India has already approved the vaccine for emergency use.